Back to Journals » International Journal of Nanomedicine » Volume 11

Controlled release hydrogen sulfide delivery system based on mesoporous silica nanoparticles protects graft endothelium from ischemia–reperfusion injury

Authors Wang W, Sun X, Zhang H, Yang C, Liu Y, Yang W, Guo C, Wang C

Received 19 January 2016

Accepted for publication 25 May 2016

Published 18 July 2016 Volume 2016:11 Pages 3255—3263


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Dr Lei Yang

Wenshuo Wang,1,* Xiaotian Sun,1,2,* Huili Zhang,3 Cheng Yang,1 Ye Liu,4,5 Wuli Yang,4,5 Changfa Guo,1 Chunsheng Wang1

1Department of Cardiac Surgery, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, 2Department of Cardiothoracic Surgery, Huashan Hospital, Fudan University, 3Department of Cardiology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University, 4State Key Laboratory of Molecular Engineering of Polymers, 5Department of Macromolecular Science, Fudan University, Shanghai, People’s Republic of China

*These authors contributed equally to this work

Abstract: Hydrogen sulfide (H2S) functions as a protective gas transmitter in various physiological and pathological processes, but the lack of ideal donors severely hampers the clinical application of H2S. This study aims to construct a controlled release H2S donor and evaluate its protective effect on graft endothelium. Mesoporous silica nanoparticles (MSNs) were synthesized using the sol–gel method and loaded with diallyl trisulfide (DATS), an H2S-releasing agent named DATS-MSN. In vitro experiments showed that DATS-MSN could alleviate endothelial cell inflammation and enhance endothelial cell proliferation and migration. In vivo experiments demonstrated that the apoptosis of graft endothelium was mitigated in the presence of DATS-MSN. Our results indicated that DATS-MSN, releasing H2S in a controlled release fashion, could serve as an ideal H2S donor.

Keywords: inflammatory response, rejection, cellular uptake, proliferation, cardiac allograft vasculopathy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]